literature

HBV mutation literature information.

Reactivation of Occult Hepatitis B Virus Infection During Long-Term Entecavir Antiviral Therapy.

PMID: 35359734 2022 Frontiers in microbiology

Table: S202G

Detection of Hepatitis B Virus M204V Mutation Quantitatively via Real-time PCR.

PMID: 34007795 2021 Journal of clinical and translational hepatology

Table: S202G

Global prevalence and phylogeny of hepatitis B virus (HBV) drug and vaccine resistance mutations.

PMID: 33893696 2021 Journal of viral hepatitis

Method: ETV resistance: Two or more amino acid substitutions are required across the HBV RT protein to confer resistance to ETV which could occur as a combination of M204I/V with one or more of the following substitutions L80I/V, I163V, I169T, V173L, L180M, A181S/T/V, T184X, A186T, S202C/G/I/R, M250I/V and/or C256S/G.

Multiple drug-resistant HBV mutation may contribute to poor response of adefovir + entecavir in entecavir-resistant patients.

PMID: 33571155 2021 Journal of infection in developing countries

Abstract: RESULTS: ETV-resistant mutants were continuously detected in 10 of the 12 patients, and multidrug-resistant (MDR) mutants, including a novel strain (rtL180M+A181V+T184A+S202G+M204V), were detected in two patients.

Virologic analysis of tenofovir resistance in a patient with chronic hepatitis B experiencing viral breakthrough during combination treatment with tenofovir disoproxil fumarate and entecavir.

PMID: 33462964 2021 Hepatology research

Abstract: Four mutations (rtS106C, rtD134N/S[N/S], rtM204V, and rtL269I) plus ETV resistance (rtL180M and rtS202G) existed when she developed viral breakthrough during ETV and TDF combination therapy in April 2013.

Abstract: In conclusion, three mutations (CN/SI) plus ETV resistance (rtL180M, rtM204V, and rtS202G) can cause tenofovir resistance.

Identification of a novel long-acting 4'-modified nucleoside reverse transcriptase inhibitor against HBV.

PMID: 33333207 2021 Journal of hepatology

Abstract: E-CFCP also reduced HBVETV-RL180M/S202G/M204V-viremia by 2 logs over 2 weeks, while ETV completely failed to reduce HBVETV-RL180M/S202G/M204V-viremia.

Abstract: E-CFCP's 4'-cyano and fluorine interact with both HBVWT-RT and HBVETV-RL180M/S202G-M204 -RT via Van der Waals and polar forces, being important for E-CFCP-triphosphate's interactions and anti-HBV potency.

Abstract: RESULTS: E-CFCP potently blocked HBVWTD1 production (IC50qPCR_cell=1.8 nM) in HepG2.2.15 cells and HBVWTC2 (IC50SB_cell=0.7 nM), entecavir (ETV)-resistant HBVETV-RL180M/S202G/

Structural features in common of HBV and HIV-1 resistance against chirally-distinct nucleoside analogues entecavir and lamivudine.

PMID: 32080249 2020 Scientific reports

Introduction: The amino acid substitutions, M204V/I and M204V/I + L180M, in HBV RT are known to cause 3TC resistance, and these mutations significantly reduce ETV effectiveness against HBV, thereby increasing the likelihood of subsequently developing greater ETV resistance through getting additional amino acid substitutions such as S202G in HBV RT.

Result: The corresponding M204V/I mutation in HBV RT has also been identified as a key mutation highly affecting HBV's sensitivity to 3TC and ETV, and in particular, triple mutations M204V/L180M/S202G render HBV completely resistant to both 3TC

7-Deaza-7-fluoro modification confers on 4'-cyano-nucleosides potent activity against entecavir/adefovir-resistant HBV variants and favorable safety.

PMID: 32084506 2020 Antiviral research

Abstract: Southern blot analysis using wild-type HBV (HBVWT)-encoding-plasmid-transfected HepG2 cells revealed that CdFA efficiently suppresses the production of HBVWT (IC50 = 153.7 nM), entecavir (ETV)-resistant HBV carrying L180M/S202G/M204V substitutions (HBVETVR; IC50 = 373.2 nM), and adefovir dipivoxil (ADV)-resistant HBV carrying A181T/N236T substitutions (HBVADVR; IC50=192.6 nM), whereas ETV and ADV were less potent against HBVETVR and HBVADVR (IC50: >1,000 and 4,02

Result: We then analyzed the interactions of ETV-TP and CdFA-TP with HBV-RT, in which three amino acid substitutions associated with HBV's resistance to ETV (L180M/S202G/M204V) have been introduced (RTETV-R).

Entecavir-resistant hepatitis B virus decreases surface antigenicity: A full genome and functional characterization.

PMID: 32216026 2020 Liver international

Abstract: Additionally, the ETV resistance mutations rtT184A/L, rtS202G and rtM250V were found among three patients.

Comprehensive Analysis of Clinically Significant Hepatitis B Virus Mutations in Relation to Genotype, Subgenotype and Geographic Region.

PMID: 33381105 2020 Frontiers in microbiology

Method: According to the most recent clinical practice guidelines of the European Association for the Study of the Liver, the following amino acid substitution profiles for HBV-resistant mutants were used: rtM204V/I (LAM resistance), rtM204I or L180M + rtM204V (LdT resistance), rtA181T/V or rtN236T (ADV resistance), rtL180M + rtM204I/V +- rtT184S/G +-

Browser Board

Co-occurred Entities

Filtrator